Lincoln Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹177Cr
- +14.9% YoY
- −5.3% QoQ
- Net profit
- ₹36Cr
- +28.6% YoY
- +200% QoQ
- Margin
- 15%
- 0 pp YoY
- +2 pp QoQ
Guidance rank: #55 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Lincoln Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.
From Lincoln Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Lincoln Pharmaceuticals Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 177 | 154 | +14.9% | 187 | -5.3% |
| Operating profit (EBITDA) | 27 | 24 | +12.5% | 25 | +8% |
| Operating margin | 15% | 15% | 0 pp | 13% | +2 pp |
| Profit before tax | 48 | 35 | +37.1% | 17 | +182.4% |
| Net profit (PAT) | 36 | 28 | +28.6% | 12 | +200% |
| EPS (₹) | 18.09 | 13.82 | +30.9% | 5.81 | +211.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q1 FY27 results?
EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
